Skip to Content
Merck

1479304

USP

Oseltamivir phosphate

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

(3R,4R,5S)-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester phosphate salt

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

200 MG

€ 531,00

€ 531,00

Check Cart for Availability
Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C16H28N2O4 ·H3PO4
CAS Number:
204255-11-8
Molecular Weight:
410.40
MDL number:
MFCD08059548
UNSPSC Code:
41116107
PubChem Substance ID:
329750621
NACRES:
NA.24

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

pharmaceutical primary standard

API family

oseltamivir

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1

InChI

1S/C16H28N2O4.H3O4P/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19;1-5(2,3)4/h9,12-15H,5-8,17H2,1-4H3,(H,18,19);(H3,1,2,3,4)/t13-,14+,15+;/m0./s1

InChI key

PGZUMBJQJWIWGJ-ONAKXNSWSA-N

Looking for similar products? Visit Product Comparison Guide

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
BP903PHR1781SML1606
Oseltamivir phosphate United States Pharmacopeia (USP) Reference Standard

USP

1479304

Oseltamivir phosphate

Oseltamivir phosphate British Pharmacopoeia (BP) Reference Standard

BP903

Oseltamivir phosphate

Oseltamivir Phosphate Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1781

Oseltamivir Phosphate

Oseltamivir phosphate ≥98% (HPLC)

Sigma-Aldrich

SML1606

Oseltamivir phosphate

manufacturer/tradename

USP

manufacturer/tradename

BP

manufacturer/tradename

-

manufacturer/tradename

-

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

certified reference material, pharmaceutical secondary standard

grade

-

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical
pharmaceutical small molecule

application(s)

pharmaceutical (small molecule)

application(s)

-

format

neat

format

neat

format

neat

format

-

API family

oseltamivir

API family

oseltamivir

API family

oseltamivir

API family

-

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

comparable product

Product No.
Description
Pricing

related product

Product No.
Description
Pricing

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H317,H319,H412

Hazard Classifications

Aquatic Chronic 3 - Eye Irrit. 2 - Skin Sens. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Henju Marjuki et al.
The Journal of infectious diseases, 210(3), 435-440 (2014-02-27)
Human infections caused by avian influenza A virus type subtype H7N9 have been associated with substantial morbidity and mortality. Emergence of virus variants carrying markers of decreased susceptibility to neuraminidase inhibitors was reported. Here we show that DAS181 (Fludase), an
Ding Yuan Oh et al.
The Journal of antimicrobial chemotherapy, 69(9), 2458-2469 (2014-05-21)
The emergence of the pandemic influenza A(H1N1)pdm09 virus in 2009 saw a significant increase in the therapeutic and prophylactic use of neuraminidase inhibitors (NAIs) to mitigate the impact of this highly transmissible virus. Prior to the pandemic, many countries stockpiled
Henju Marjuki et al.
Journal of virology, 89(10), 5419-5426 (2015-03-06)
Human infections by avian influenza A(H7N9) virus entail substantial morbidity and mortality. Treatment of infected patients with the neuraminidase (NA) inhibitor oseltamivir was associated with emergence of viruses carrying NA substitutions. In the NA inhibition (NI) assay, R292K conferred highly
Eric J Stavale et al.
PloS one, 10(3), e0121662-e0121662 (2015-03-19)
Our lead iminosugar analog called UV-4 or N-(9-methoxynonyl)-1-deoxynojirimycin inhibits activity of endoplasmic reticulum (ER) α-glucosidases I and II and is a potent, host-targeted antiviral candidate. The mechanism of action for the antiviral activity of iminosugars is proposed to be inhibition
Aihua Song et al.
Antiviral research, 111, 60-68 (2014-09-15)
Influenza virus is a global health concern due to its unpredictable pandemic potential. Frequent mutations of surface molecules, hemagglutinin (HA) and neuraminidase (NA), contribute to low efficacy of the annual flu vaccine and therapeutic resistance to standard antiviral agents. The
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service